Q: This company seems to have reasonable ROE (just under 20) and good growth but has sold off with several large blocks transacting recently despite positive analyst coverage. It reports this week so I don't plan to jump into a position but I wanted 5i's opinion on whether mid $30's represents an attractive entry point for a company that has exposure to a variety of Pharma companies? Would it be a buy, sell or hold for you and what would it take in terms of a news event or drop in price to make it a buy? What do you like and/or dislike about the company?
Thanks!
Thanks!